Skip to content

KLRS KLRS Total Liabilities

Total Liabilities at other companies

Merck & Co. logo
Merck & Co.MRK
$229M
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$9.45B+15.8%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$57.75M-10.0%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$150.96M+7.8%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$193.91M+2.6%
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's total liabilities?
KLRS (KLRS) reported total liabilities of $41.25M in Q1 2026.
How has KLRS's total liabilities changed year-over-year?
KLRS's total liabilities increased by 5.2% year-over-year, from $39.22M to $41.25M.
What is the long-term trend for KLRS's total liabilities?
Over 4 years (2021 to 2025), KLRS's total liabilities has grown at a -8.5% compound annual growth rate (CAGR), from $61.33M to $42.92M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.